Van Peer A, Vercauteren M, Noorduin H, Woestenborghs R, Heykants J
Eur J Clin Pharmacol. 1986;30(2):245-7. doi: 10.1007/BF00614313.
Alfentanil 100 micrograms/kg was administered as an i.v. bolus to 9 patients with severe chronic renal dysfunction (creatinine clearance 1.0 +/- 1.2 ml/min) requiring regular haemodialysis. Plasma alfentanil concentrations were measured by a specific radioimmunoassay. Individual plasma concentration-time curves were fitted to a two-compartment open model. Mean distribution and elimination half-lives were 3.7 min and 58 min, respectively. The apparent volumes of distribution of the central compartment and the total volume of distribution at steady-state were 91 ml/kg and 304 ml/kg, respectively. Alfentanil plasma clearance was 5.3 +/- 2.5 ml/min/kg. All the patients tolerated alfentanil well and no side-effects nor delayed recovery were observed.
对9例需要定期血液透析的严重慢性肾功能不全(肌酐清除率1.0±1.2ml/分钟)患者静脉推注100微克/千克阿芬太尼。采用特异性放射免疫分析法测定血浆阿芬太尼浓度。将个体血浆浓度-时间曲线拟合为二室开放模型。平均分布半衰期和消除半衰期分别为3.7分钟和58分钟。中央室的表观分布容积和稳态时的总体分布容积分别为91ml/千克和304ml/千克。阿芬太尼血浆清除率为5.3±2.5ml/分钟/千克。所有患者对阿芬太尼耐受性良好,未观察到副作用或恢复延迟。